Literature DB >> 16098118

Acute interstitial pneumonitis during chemotherapy for haematological malignancy.

K Nakase1, K Tsuji, S Nagaya, S Tamaki, M Tanigawa, T Ikeda, E Miyanishi, H Shiku.   

Abstract

Fourteen adult patients with haematological malignancies (eight non-Hodgkin's lymphoma, one multiple myeloma, one chronic lymphocytic leukaemia, two acute lymphoblastic leukaemia and two acute myeloid leukaemia) developed acute interstitial pneumonitis (IP) during the course of chemotherapy. All patients manifested high fever over 38 degrees C, bilateral diffuse pulmonary interstitial infiltrates in the chest radiograph and severe hypoxia without hypercapnia in the arterial blood gas analysis. Pathogenic microorganisms were not detected in repeated examinations in any patient. Chemotherapy given included various anti-neoplastic drugs. Five patients had received granulocyte colony-stimulating factor (G-CSF) for chemotherapy-induced leucopenia. The onset was associated with an increase of leucocytes in 10 patients. All patients were treated with high dose steroid hormone and broad spectrum antibiotics with or without anti-fungal agents, and three required mechanical ventilation. Eleven patients quickly recovered from these situations, whereas three died. Autopsies were done in two patients and disclosed pneumocystis carinii (PC) pneumonitis in one and non-specific pulmonary congestive oedema and fibrosis in the other. In conclusion, IP of unknown cause could develop in patients with various haematological malignancies especially at the recovery phase of chemotherapy-induced leucopenia irrespective of the previous G-CSF administration. High dose steroid hormone should be used as therapy for such patients as soon as possible after exclusion of an infective aetiology.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16098118     DOI: 10.1111/j.1365-2354.2005.00589.x

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  5 in total

1.  Meta-Analysis of Risk Factors and Incidence of Interstitial Pneumonia With CHOP-Like Regimens for Non-Hodgkin Lymphoma.

Authors:  Jing Yang; Limin Chai; Junting Jia; Liping Su; Zhiying Hao
Journal:  Front Oncol       Date:  2022-06-01       Impact factor: 5.738

2.  Increased incidence of interstitial pneumonia by CHOP combined with rituximab.

Authors:  Daisuke Ennishi; Yasuhito Terui; Masahiro Yokoyama; Yuko Mishima; Shunji Takahashi; Kengo Takeuchi; Kazuma Ikeda; Mitsune Tanimoto; Kiyohiko Hatake
Journal:  Int J Hematol       Date:  2008-05       Impact factor: 2.490

3.  Fatal Interstitial Pneumonitis Rapidly Developed after the First Cycle of CHOP with Etoposide Combination Chemotherapy in a Patient with Lymphoma.

Authors:  Hyung Chul Park; Jae-Sook Ahn; Deok-Hwan Yang; Sung-Hoon Jung; In-Jae Oh; Song Choi; Seung-Shin Lee; Mi-Young Kim; Yeo-Kyeoung Kim; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Tuberc Respir Dis (Seoul)       Date:  2013-05-31

4.  Chemotherapy-Associated Pulmonary Toxicity-Case Series from a Single Center.

Authors:  Tilak Tvsvgk; Ajay Handa; Kishore Kumar; Deepti Mutreja; Shankar Subramanian
Journal:  South Asian J Cancer       Date:  2021-11-11

5.  Impact of interstitial pneumonia on the survival and risk factors analysis of patients with hematological malignancy.

Authors:  Wei-Liang Chen; Yu-Tzu Tsao; Tsun-Hou Chang; Tsu-Yi Chao; Woei-Yau Kao; Yeu Chin Chen; Ching-Liang Ho
Journal:  Biomed Res Int       Date:  2013-09-04       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.